Pyxis Oncology reported a net loss of $25.3 million ($0.40 per share) for the quarter ended June 30, 2026, compared to a $18.4 million loss in the prior year period. The company completed a private placement financing on July 2, 2026, securing approximately $50 million in upfront gross proceeds and up to an additional $64 million if warrants are exercised. This capital, combined with existing cash reserves of $34.5 million as of June 30, extends the company's cash runway into the second quarter of 2027. Clinical updates include expected data releases for MICVO monotherapy in Fall 2026 and combination therapy with pembrolizumab in Q4 2026. Pyxis Oncology is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers.
